Delhi Daily News |
Merck four-week hep C regimen with Gilead's Sovaldi comes up short Reuters (Reuters) - An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, ... Merck's Four-Week Hepatitis C Regimen Fails to Top GileadBusinessweek Merck's four week Hepatitis C regimen falls shortDumb-Out Merck & Co to Help Cure Hepatitis in 4 Weeks with Gilead's SovaldiWallStreet OTC TheStreet.com all 15 news articles » |
More...